“Patients who had a combination of intravenous vitamin C and chemotherapy did significantly better than the national average of patients just taking chemotherapy alone…”
Conventional oncology has not managed to improve the lives of pancreatic cancer (PC) patients much in the past few decades. The five-year survival stats for the average PC patient, depending on your stage at diagnosis, is usually in the single digits. By themselves, intravenous vitamin C, gemcitabine and curcumin show only modest efficacy against pancreatic cancer. But if you “integrate” all three therapies then you may be on to something!
The concept of integrating therapies simply means that one therapy such as vitamin C therapy can enhance the efficacy of a second therapy such as gemcitabine to double the average survival time for PC patients.
“Patients who had a combination of intravenous vitamin C and chemotherapy did significantly better than the national average of patients just taking chemotherapy alone…
However, one significant advance in the treatment of pancreatic cancer was the introduction of a chemotherapy agent, gemcitabine. Another improvement was the therapy consisting of a combination chemotherapy. Unfortunately side effects for both of these therapies limits their extended use…
The average survival for patients treated with gemcitabine is approximately six months. In this study, the combination of gemcitabine and intravenous vitamin C resulted in an average survival of 12 months with one patient surviving for almost 2½ years…”
“Curcuminhas a potent antiproliferative activity and can also potentiate the antitumor effect of gemcitabine. This study was undertaken to evaluate the activity and feasibility of gemcitabine in combination with curcumin in patients with advanced pancreatic cancer…
One of 11 evaluable patients (9%) had partial response, 4 (36%) had stable disease, and 6 (55%) had tumor progression. Time to tumor progression was 1-12 mo (median 2½), and overall survival was 1-24 mo (median 5). Low compliance for curcumin at a dose of 8,000 mg/day, when taken together with systemic gemcitabine, may prevent the use of high doses of oral curcuminneeded to achieve systemic effect…”
“Based on a review of these studies, it is evident that better bioavailability of formulated curcumin (CU) products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism”
A search of the Pubmed database for the word curcumin yields 601 studies spaning health topics from multiple myeloma and colorectal cancer, to chemotherapies that synergizes with CU, to Alzheimer’s Disease, arthritis and more. Based on years of reading studies and personal accounts, I think it is safe to say that CU supplementation is safe and relatively inexpensive.
I have read about myeloma patients taking daily doses of CU from 400 milligrams to 8 grams (1000 milligrams = 1 gram). By almost any measure, CU is a safe, inexpensive wonder drug.
The only challenge is that CU is famously difficult to absorb in the body. In other words, a person has to mix curcumin with some sort of fat (coconut oil, chocolate, etc.) or take a brand of curcumin capsule that is already formulated to be more “bioavailable” in order to derive the full benefit of CU.
The study linked and exerpted below reviews different formulations of CU. The study itself lists the three most bioavailable formulation/brand of CU and I’ve added an excerpt from a further review from Consumerlab.com that lists four additional bioavailable brands of CU.
I consult the independent evaluation service Consumerlab.com frequently. For one low annual payment, I can read about and evaluate all of the nutritional supplement that I take.
“Curcumin is a widely studied natural compound which has shown tremendous in vitro therapeutic potential. Despite that, the clinical efficacy of the native CU is weak due to its low bioavailability and high metabolism in the gastrointestinal tract. During the last decade, researchers have come up with different formulations with a focus on improving the bioavailability of curcumin. As a result, a significant number of bioavailable curcumin-based formulations were introduced with the varying range of enhanced bioavailability.
The purpose of this review is to collate the published clinical studies of CU products with improved bioavailability over conventional (unformulated) CU. Based on the literature search, 11 curcumin formulations with available human bioavailability and pharmacokinetics data were included in this review. Further, the data on clinical study design, analytical method, pharmacokinetic parameters and other relevant details of each formulation were extracted.
Based on a review of these studies, it is evident that better bioavailability of formulated curcumin products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism. The review hopes to provide a quick reference guide for anyone looking information on these bioavailable curcumin formulations.
exhibited over 100-fold higher bioavailability relative to reference unformulated CU. Suggested mechanisms accounting for improved bioavailability of the formulations and details on the bioanalysis methods are also discussed.”
APPIP ERROR: amazonproducts[
AccessDeniedAwsUsers|The Access Key Id AKIAJAJ37JVNL7OUU4CA is not enabled for accessing this version of Product Advertising API. Please migrate your credentials as referred here https://webservices.amazon.com/paapi5/documentation/migrating-your-product-advertising-api-account-from-your-aws-account.html.
[…] Intravenous Vitamin C, Curcumin as Integrative Pancreatic Cancer Therapies […]Reply